Supplementation with carnitine for weight loss: a biochemical approach
Article Sidebar
Main Article Content
- Carnitine
- Lipid metabolism
- Weight loss
Winter SC. Treatment of carnitine deficiency. J Inherit MetabDis. 2003; 26: 171-80.2.Matera M, Bellinghieri G, Costantino G, Santoro D, CalvaniM, Savica V. History of L-carnitine: implications for renaldisease. J Ren Nutr. 2003; 13: 2-14.3.Rebouche CJ. Kinetics, pharmacokinetics, and regulation ofL-carnitine and acetyl-L-carnitine metabolism. Ann N Y AcadSci. 2004; 1033: 30-41.4.Rebouche C. Carnitine.In: Shils M, Shike M, Ross A, et al.Modern nutrition in health and disease. Philadelphia:Lippincott, Williams and Wilkins; 2006. p. 537-44.5.Wanders RJA, Vreken P, Ferdinandusse S, Jansen GA,Waterham HR, van Roermund CWT, et al. Peroxisomal fattyacid α- and β-oxidation in humans: enzymology, peroxisomalmetabolite transporters and peroxisomal diseases. BiochemSoc Trans. 2001; 29: 250-67.6.Peluso G, Barbarisi A, Savica V, Reda E, Nicolai R, BenattiP, et al. Carnitine: an osmolyte that plays a metabolic role. JCell Biochem. 2000; 80: 1-10.7.Pessayre D. Role of mitochondria in non-alcoholic fatty liverdisease. J Gastroenterol Hepatol. 2007; 22( Suppl 1): S20-7.8.Eaton S, Fukumoto K, Stefanutti G, Spitz L, Zammit VA,Pierro A. Myocardial carnitine palmitoyltransferase I as atarget for oxidative modification in inflammation and sepsis.Biochem Soc Trans. 2003; 31: 1133-6.9.Crill CM, Helms RA. The use of carnitine in pediatric nutrition.Nutr Clin Pract. 2007; 22: 204-13.10. Poirier Y, Antonenkov VD, Glumoff T, Hiltunen JK.Peroxisomal beta-oxidation-a metabolic pathway with multiplefunctions. Biochim Biophys Acta. 2006; 1763: 1413-26.11. Wanders RJ, Ferdinandusse S, Brites P, Kemp S. Peroxisomes,lipid metabolism and lipotoxicity. Biochim Biophys Acta.2010; 1801: 272-80.12. Dutta-Roy AK. Cellular uptake of long-chain fatty acids: roleof membrane-associated fatty-acid-binding/transport proteins.Cell Mol Life Sci. 2000; 57:1360-72.13. McGarry JD. Travels with carnitine palmitoyltransferase I:from liver to germ cell with stops in between. Biochem SocTrans. 2001; 29: 241-5.14. Ronnett GV, Kleman AM, Kim EK, Landree LE, Tu Y. Fattyacid metabolism, the central nervous system, and feeding.Obesity. 2006; 14 (Suppl 5): S201-7.15. Baker A, Graham IA, Holdsworth M, Smith SM, TheodoulouFL. Chewing the fat: beta-oxidation in signaling anddevelopment. Trends Plant Sci. 2006; 11: 124-32.16. Demizieux L. Control and regulation of mitochondrialoxidation of long-chained fatty acids. J Soc Biol. 2005; 199:143-55.17. Bennet MJ, Rinaldo P, Strauss AW. Inborn errors of mito-chondrial fatty acid oxidation. Clin Rev Clin Lab Sci. 2000;37: 1-44.18. Harris WS, Bulchandani D. Why do omega-3 fatty acids lowerserum triglycerides? Curr Opin Lipidol. 2006; 17: 387-93.19. Czeczot H, Scibior D. Role of L-carnitine in metabolism,nutrition and therapy. Postepy Hig Med Dosw. 2005; 59: 9-19.20. Longo N, Amat di San Filippo C, Pasquali M. Disorders ofcarnitine transport and the carnitine cycle. Am J Med Genet CSemin Med Genet. 2006; 142C: 77-85.21. Labadaridis J, Mavridou I, Sarafidou G, Alexiou N, CostalosC, Michelakakis H. Carnitine supplementation and ketogenesisby small-for-date neonates on medium-and long-chain fattyacid formulae. Biol Neonate. 2000; 77: 25-8.22. Infante JP, Huszagh VA. Secondary carnitine deficiency andimpaired docosahexaenoic (22:6n-3) acid synthesis: a commondenominator in the pathophysiology of diseases of oxidative
Colombia MédicaVol. 42 Nº 4, 2011 (Octubre-Diciembre)phosphorilation and β-oxidation. FEBS letters. 2000; 468: 1-5.23. Laviano A, Meguid MM, Guijarro A, Muscaritoli M, CascinoA, Preziosa I, et al. Antimyopathic effects of carnitine andnicotine. Curr Opin Clin Nutr Metab Care. 2006; 9: 442-8.24. Iyer RN, Khan AA, Gupta A, Vajifdar BU, Lokhandwala YY.L-carnitine moderately improves the exercise tolerance inchronic stable angina. J Assoc Physicians India. 2000; 48:1050-2.25. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J,Lysiak-Szydlowska W. Influence of L-carnitine and itsderivatives on myocardial metabolism and function in ischemicheart disease and during cardiopulmonary bypass. CardiovascRes. 2001; 51: 21-9.26. Rizos I. Three-year survival of patients with heart failurecaused by dilated cardiomyopathy and L-carnitineadministration. Am Heart J. 2000; 139: S120-3.27. Gürlek A, Tutar E, Akçil E, Dinçer I, Erol C, Kocatürk PA,Oral D. The effects of L-carnitine treatment on left ventricularfunction and erythrocyte superoxide dismutase activity inpatients with ischemic cardiomyopathy. Eur J Heart Fail.2000; 2: 189-93.28. Gaby AR. Nutritional treatments for acute myocardialinfarction. Altern Med Rev. 2010; 15: 113-23.29. Sirtori CR, Calabresi L, Ferrara S, Pazzucconi F, Bondioli A,Baldassarre D, Birreci A, Koverech A. L-carnitine reducesplasma lipoprotein(a) levels in patients with hyper Lp(a). NutrMetab Cardiovasc Dis. 2000; 10: 247-51.30. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L,Fogari R. The effect of L-carnitine on plasma lipoprotein(a)levels in hypercholesterolemic patients with type 2 diabetesmellitus. Clin Ther. 2003; 25: 1429-39.31. Cakir N, Yetkin I, Karakoc A, Karakan T , Ayvaz G, ArslanM. L-carnitine in the treatment of painful diabetic neuropathyand its effect on plasma beta-endorphin levels. Curr Ther ResClin Exp. 2000; 61: 871-6.32. Kuratsune H. Chronic fatigue syndrome. Ryoikibetsu ShokogunShirizu. 2000; 32: 531-4.33. Karanth J, Jeevaratnam K. Effect of carnitine supplementationon mitochondrial enzymes in liver and skeletal muscle of ratafter dietary lipid manipulation and physical activity. IndianJ Exp Biol. 2010; 48: 503-10.34. DaVanzo WJ, Ullian ME. L-carnitine administration reversesacute mental status changes in a chronic hemodialysis patientwith hepatitis C infection. Clin Nephrol. 2002; 57: 402-05.35. Moretti S, Famularo G, Marcellini S, Boschini A, Santini G,Trinchieri V, et al. L-carnitine reduces lymphocyte apoptosisand oxidant stress in HIV-1-infected subjects treated withzidovudine and didanosine. Antioxid Redox Signal. 2002; 4:391-403.36. Benvenga S, Ruggeri RM, Russo A, Lapa D, Campenni A,Trimarchi F. Usefulness of L-carnitine, a naturally occurringperipheral antagonist of thyroid hormone action, in iatrogenichyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab. 2001; 86:3579-94.37. Lenzi A, Lombardo F, Sgrò P, Salacone P, Caponecchia L,Dondero F, et al. Use of carnitine therapy in selected cases ofmale factor infertility: a double-blind crossover trial. FertilSteril. 2003; 79: 292-300.38. Veselá E, Racek J, Trefil L, Jankovy’ch V, Pojer M. Effect ofL-carnitine supplementation in hemodialysis patients. Nephron.2001; 88: 218-23.39. Romagnoli GF, Naso A, Carraro G, Lidestri V. Beneficialeffects of L-carnitine in dialysis patients with impaired leftventricular function: an observational study. Curr Med ResOpin. 2002; 18: 172-5.40. Whitfield J, Smith T, Sollohub H, Sweetman L, Roe CR.Clinical effects of L-carnitine supplementation on apnea andgrowth in very low birth weight infants. Pediatrics. 2003; 111:477-82.41. Peña-Quintana L, Sanjurjo-Crespo P. Diagnostic approachand treatment of inherited mitochondrial fatty acid oxidationdisorders. An Esp Pediatr. 2001; 55: 524-34.42. Stanley CA. Carnitine deficiency disorders in children. Ann NY Acad Sci 2004; 1033: 42-51.43. Vaz FM, Wanders RJA. Carnitine biosynthesis in mammals.Biochem J. 2002; 361: 417-29.44 Krajcovicová-Kudlácková M, Simoncic R, Béderová A,Babinská K, Béder I. Correlation of carnitine levels tomethionine and lysine intake. Physiol Res. 2000; 49: 399-402.45. Pace S, Longo A, Toon S, Rolan P, Evans AM. Pharmaco-kinetics of propionyl-L-carnitine in humans: evidence forsaturable tubular reabsorption. Br J Clin Pharmacol. 2000;50: 441-8.46. Fokkema MR, van Rieke HM, Bauermann OJ, Smit EN,Muskiet FA. Short-term carnitine supplementation does notaugment LCPomega3 status of vegans and lacto-ovo-vegetarians. J Am Coll Nutr. 2005; 24: 58-64.47. Spiekerkoetter U, Bastin J, Gillingham M, Morris A, WijburgF, Wilcken B. Current issues regarding treatment ofmitochondrial fatty acid oxidation disorders. J Inherit MetabDis. 2010; 33: 555-61.48. Baek JE, Yang WS, Chang JW, Kim SB, Park SK, Park JS, LeeSK. Fatty acid-bearing albumin induces VCAM-1 expressionthrough c-Src kinase-AP-1/NF-kB pathways: effect of L-carnitine. Kidney Blood Press Res. 2010; 33: 72-84.49. Chapela SP, Kriguer N, Fernández EH, Stella CA. Involvementof L-carnitine in cellular metabolism: beyond Acyl-CoAtransport. Mini Rev Med Chem. 2009; 9: 1518-26.50. Karanth J, Jeevaratnam K. Effect of carnitine supplementationon mitochondrial enzymes in liver and skeletal muscle of ratafter dietary lipid manipulation and physical activity. IndianJ Exp Biol. 2010; 48: 503-10.51. Laforêt P, Vianey-Saban C. Disorders of muscle lipidmetabolism: diagnostic and therapeutic challenges. Neuro-muscul Disord. 2010; 20: 693-700.52. Berardo A, DiMauro S, Hirano M. A diagnostic algorithm formetabolic myopathies. Curr Neurol Neurosci Rep. 2010; 10:118-26.53. Bökenkamp A, Ludwig M. Disorders of the renal proximaltubule. Nephron Physiol. 2011; 118: 1-6.54. Karlic H, Lohninger A. Supplementation of L-carnitine inathletes: does it make sense? Nutrition. 2004; 20: 709-15.
Colombia MédicaVol. 42 Nº 4, 2011 (Octubre-Diciembre)55. Jacobs PL, Goldstein ER. Long-term glycine propionyl-l-carnitine supplemention and paradoxical effects on repeatedanaerobic sprint performance. J Int Soc Sports Nutr. 2010; 7:35.56. Kraemer WJ, Volek JS, Dunn-Lewis C. L-carnitine supple-mentation: influence upon physiological function. Curr SportsMed Rep. 2008; 7: 218-23.57. Villani RG, Gannon J, Self M, Rich PA. L-Carnitinesupplementation combined with aerobic training does notpromote weight loss in moderately obese women. Int J SportNutr Exerc Metab. 2000; 10: 199-207.58. Melton SA, Keenan MJ, Stanciu CE, Hegsted M, Zablah-Pimentel EM, O’Neil CE, et al. L-carnitine supplementationdoes not promote weight loss in ovariectomized rats despiteendurance exercise. Int J Vitam Nutr Res. 2005; 75: 156-60.59. Elmslie JL, Porter RJ, Joyce PR, Hunt PJ, Mann JI. Carnitinedoes not improve weight loss outcomes in valproate-treatedbipolar patients consuming an energy-restricted, low-fat diet.Bipolar Disord. 2006; 8 (5 Pt 1): 503-7.60. Saper RB, Eisenberg DM, Phillips RS. Common dietarysupplements for weight loss. Am Fam Physician. 2004; 70:1731-8
Downloads
- José Henry Osorio, Morteza Pourfarzam, Levels of carnitine and acylcarnitines in reconstituted red blood cell samples washed with different concentrations of saline solutions , Colombia Medica: Vol. 41 No. 4 (2010)
- José Henry Osorio, Evolution and changes in the physician-patient relationship , Colombia Medica: Vol. 42 No. 3 (2011)
- José Henry Osorio, Evidence in Colombia of 625G>A polymorphism in the short chain acyl-CoA dehydrogenase gene, a variation which could cause glutaric aciduria in our populations , Colombia Medica: Vol. 41 No. 3 (2010)
- José Henry Osorio, Implementation of a method using tritiated substrates as a diagnostic tool for OCTN2 deficiency. , Colombia Medica: Vol. 39 No. 4 (2008)
Accepted 2011-11-23
Published 2024-07-11
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The copy rights of the articles published in Colombia Médica belong to the Universidad del Valle. The contents of the articles that appear in the Journal are exclusively the responsibility of the authors and do not necessarily reflect the opinions of the Editorial Committee of the Journal. It is allowed to reproduce the material published in Colombia Médica without prior authorization for non-commercial use